Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with some weeks of delay.
Pharma company Sobi to acquire Synagis from AstraZeneca
November 15, 2018

Swedish Orphan Biovitrum AB (Sobi) has entered into agreements to acquire the perpetual rights to the drug Synagis in the US from AstraZeneca and to participate in 50% of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to SEK 13.6bn consisting of SEK 9.1bn in cash and SEK 4.5bn equivalent in newly issued Sobi shares.

ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: